Aligos Therapeutics, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Aligos Therapeutics, Inc. (Nasdaq: ALGS) develops targeted antiviral and liver disease therapies addressing unmet needs in chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, COVID-19, and hepatitis delta virus (HDV). The company's lead product candidate, pevifoscorvir sodium (previously ALG-000184), is an oral small molecule capsid assembly modulator (CAM-E) in Phase 2 monotherapy for chronic HBV infection, demonstrating best-in-class reductions in viral markers including HBV DNA, RNA, HBsAg, HBeAg, and HBcrAg in long-term Phase 1 studies with full 96-week data presented at AASLD The Liver Meeting 2025; ALG-055009, an oral thyroid hormone receptor beta (THR-β) agonist in Phase 2 for MASH and obesity, achieved statistically significant liver fat reductions in the Phase 2a HERALD study topline results in September 2024 with favorable tolerability including in GLP-1 combination; ALG-097558, a ritonavir-free pan-coronavirus protease inhibitor in Phase 1/2 supported by over $13.8 million in NIAID/NIH funding, began three clinical trials in 2024 showing superior potency against SARS-CoV-2 variants; preclinical programs include proprietary antisense oligonucleotide (ASO) platforms for chronic HBV and HDV targeting viral genome destruction with improved toxicity profiles. In February 2025, Aligos completed a $105 million private placement financing to support pipeline advancement including the Phase 2 B-SUPREME study for pevifoscorvir sodium dosing initiated in August 2025 with interim data expected in 2026; Phase 1 studies for pevifoscorvir sodium in special populations and drug-drug interactions are ongoing under NIAID contract. Founded in 2018 and headquartered in South San Francisco, California, the company operates primarily in the United States with additional facilities in Heverlee, Belgium, and Shanghai, China, focusing on clinical-stage biopharmaceutical development for global markets in virology and hepatology.
Company News
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
Aligos Therapeutics (NASDAQ:ALGS) & Voyager Therapeutics (NASDAQ:VYGR) Head-To-Head Analysis
Aligos Therapeutics, Inc. $ALGS Shares Bought by Bank of America Corp DE
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Receives Consensus Rating of “Moderate Buy” from Analysts